Opaleye Management’s Protalix BioTherapeutics PLX Stock Holding History

Opaleye Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$738K	Sell	340,000 -2,138,176	-86%	-$5.31M	0.1%	51
2025 Q4	$4.46M	Sell	2,478,176 -102,380	-4%	-$209K	0.59%	34
2025 Q3	$5.73M	Buy	+2,580,556	New	+$4.2M	0.81%	26
2019 Q3	–	Sell	-100,000	Closed	-$469K	–	55
2019 Q2	$469K	Buy	+100,000	New	+$423K	0.14%	41
2019 Q1	–	Sell	-250,000	Closed	-$777K	–	58
2018 Q4	$777K	Hold	250,000	–	–	0.29%	41
2018 Q3	$1.82M	Sell	250,000 -60,000	-19%	-$301K	0.46%	39
2018 Q2	$1.33M	Sell	310,000 -16,000	-5%	-$71.1K	0.35%	33
2018 Q1	$1.76M	Buy	326,000 +143,500	+79%	+$944K	0.5%	32
2017 Q4	$1.21M	Buy	+182,500	New	+$1.23M	0.39%	31

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management's PLX Position: Q1 2026 in Review

Opaleye Management reduced its Protalix BioTherapeutics (PLX) stake by 86% in Q1 2026, selling an estimated $5.31M and leaving 340,000 shares worth $738K. The position accounts for 0.1% of the portfolio, ranked #51.

Opaleye Management first reported a position in PLX in Q4 2017 and has held it in 9 quarters since. The position peaked at $5.73M in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Opaleye Management held 340,000 shares of Protalix BioTherapeutics worth $738K as of Q1 2026.
Opaleye Management sold 2,138,176 Protalix BioTherapeutics shares in Q1 2026, an estimated $5.31M.
Protalix BioTherapeutics made up 0.1% of Opaleye Management's portfolio in Q1 2026, its #51 holding.
Opaleye Management first reported a position in Protalix BioTherapeutics in Q4 2017 and has held it in 9 quarters since.
Opaleye Management's Protalix BioTherapeutics position peaked at $5.73M in Q3 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.